Widmann Financial Services Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,737 shares of the company’s stock after selling 69 shares during the period. Johnson & Johnson accounts for 2.3% of Widmann Financial Services Inc.’s investment portfolio, making the stock its 11th biggest position. Widmann Financial Services Inc.’s holdings in Johnson & Johnson were worth $2,611,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Family CFO Inc purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $26,000. Steward Financial Group LLC purchased a new position in Johnson & Johnson in the 4th quarter worth $34,000. Joseph P. Lucia & Associates LLC purchased a new position in Johnson & Johnson in the 1st quarter worth $38,000. Advocacy Wealth Management Services LLC raised its position in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter worth $49,000. 68.78% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts recently commented on the stock. Citigroup decreased their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Finally, UBS Group decreased their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $189.89.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.48 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. Johnson & Johnson’s payout ratio is currently 65.79%.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Are Baidu’s Delisting Fears a Good Entry for New Investors?
- Market Fundamentals Drive Results For The Williams Companies
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.